FibroGen(FGEN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FGEN FibroGen

Not Yet Opened 12-10 16:00:00 EST

8.82

+0.32

+3.70%

盘后8.82

+0.000.00%

16:04 EST

High8.98	Low8.42	Vol15.67K
Open8.42	D1 Closing8.51	Amplitude6.58%
Mkt Cap35.68M	Tradable Cap31.96M	Total Shares4.05M
T/O136.70K	T/O Rate0.43%	Tradable Shares3.62M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"FGEN","market":"US","secType":"STK","nameCN":"FibroGen","latestPrice":8.82,"timestamp":1765400400000,"preClose":8.505,"halted":0,"volume":15670,"hourTrading":{"tag":"盘后","latestPrice":8.82,"preClose":8.82,"latestTime":"16:04 EST","volume":7,"amount":61.74,"timestamp":1765400642624},"delay":0,"floatShares":3623701,"shares":4045445,"eps":53.37957,"marketStatus":"Not Yet Opened","change":0.315,"latestTime":"12-10 16:00:00 EST","open":8.42,"high":8.98,"low":8.42,"amount":136700.3707,"amplitude":0.065844,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":53.37957,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765443600000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1415941200000,"exchange":"NASDAQ","adjPreClose":8.505,"preHourTrading":{"tag":"盘前","latestPrice":8.4,"preClose":8.505,"latestTime":"08:00 EST","volume":1,"amount":8.4,"timestamp":1765371611502},"postHourTrading":{"tag":"盘后","latestPrice":8.82,"preClose":8.82,"latestTime":"16:04 EST","volume":7,"amount":61.74,"timestamp":1765400642624},"volumeRatio":0.847229,"impliedVol":1.651,"impliedVolPercentile":0.9609},"requestUrl":"/m/hq/s/FGEN","defaultTab":"news","newsList":[{"id":"2588669980","title":"FibroGen to Present at Oppenheimer Movers in Rare Disease Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2588669980","media":"Reuters","labels":["executive","conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588669980?lang=en_us&edition=fundamental","pubTime":"2025-12-03 05:05","pubTimestamp":1764709511,"startTime":"0","endTime":"0","summary":"FibroGen Inc. will participate in the Oppenheimer Movers in Rare Disease Summit on December 11, 2025, in New York, NY. Chief Executive Officer Thane Wettig is scheduled to join a panel titled \"Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts\" at 12:15 PM ET at the Sofitel New York. The FibroGen management team will also be available for one-on-one meetings with investors during the conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FibroGen Inc. published the original content used to generate this news brief via GlobeNewswire  on December 02, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL7qbnJK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2210149790.SGD","FGEN","LU2210150020.SGD","BK4588","BK4505","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","BK4585","BK4139","IE00B64PRP62.GBP","NDAQ","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2582836510","title":"Analysts Are Bullish on Top Healthcare Stocks: Akebia Therapeutics (AKBA), FibroGen (FGEN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582836510","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582836510?lang=en_us&edition=fundamental","pubTime":"2025-11-11 19:50","pubTimestamp":1762861820,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Akebia Therapeutics (AKBA – Research Report), FibroG...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-akebia-therapeutics-akba-fibrogen-fgen-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-akebia-therapeutics-akba-fibrogen-fgen-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","XLV","LABU","FGEN","BK4112","LU0128526141.USD","XBI","BK4585","BK4505","HCSG","BK4588","BK4139","LU0029874061.USD","BK4581","AKBA"],"gpt_icon":0},{"id":"2582354837","title":"FibroGen’s Strategic Moves and Financial Outlook: Hold Rating Amid Uncertainties","url":"https://stock-news.laohu8.com/highlight/detail?id=2582354837","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582354837?lang=en_us&edition=fundamental","pubTime":"2025-11-11 17:15","pubTimestamp":1762852535,"startTime":"0","endTime":"0","summary":"William Blair analyst Andy Hsieh has reiterated their neutral stance on FGEN stock, giving a Hold rating on October 28. Andy Hsieh has given his Ho...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/fibrogens-strategic-moves-and-financial-outlook-hold-rating-amid-uncertainties-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/fibrogens-strategic-moves-and-financial-outlook-hold-rating-amid-uncertainties-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FGEN"],"gpt_icon":0},{"id":"2582677339","title":"FibroGen’s Strategic Moves and Financial Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2582677339","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582677339?lang=en_us&edition=fundamental","pubTime":"2025-11-11 12:09","pubTimestamp":1762834183,"startTime":"0","endTime":"0","summary":"FibroGen ( ($FGEN) ) has released its Q3 earnings. Here is a breakdown of the information FibroGen presented to its investors. FibroGen, Inc. is a ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fibrogens-strategic-moves-and-financial-highlights?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fibrogens-strategic-moves-and-financial-highlights?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","FGEN","BK4139"],"gpt_icon":0},{"id":"2582388508","title":"FibroGen reports Q3 EPS ($3.25), consensus ($4.01)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582388508","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582388508?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:15","pubTimestamp":1762809329,"startTime":"0","endTime":"0","summary":"Reports Q3 revenue $1.08M, consensus $1.64M. “With the completion of the transformative sale of our FibroGen (FGEN) China operations, we have signi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fibrogen-reports-q3-eps-3-25-consensus-4-01-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fibrogen-reports-q3-eps-3-25-consensus-4-01-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FGEN"],"gpt_icon":0},{"id":"2582800886","title":"FibroGen Q3 EPS continuing operations $(3.50) Beats $(4.00) Estimate, Sales $1.076M Miss $1.640M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582800886","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582800886?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:04","pubTimestamp":1762808657,"startTime":"0","endTime":"0","summary":"FibroGen (NASDAQ:FGEN) reported quarterly losses of $(3.50) per share which beat the analyst consensus estimate of $(4.00) by 12.61 percent. This is a 17.65 percent increase over losses of $(4.25) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48766037/fibrogen-q3-eps-continuing-operations-3-50-beats-4-00-estimate-sales-1-076m-miss-1-640m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"FibroGen Q3 EPS continuing operations $(3.50) Beats $(4.00) Estimate, Sales $1.076M Miss $1.640M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FGEN"],"gpt_icon":0},{"id":"2582074978","title":"FibroGen posts Q3 revenue of $1.1 million with net loss of $13.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582074978","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582074978?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:02","pubTimestamp":1762808552,"startTime":"0","endTime":"0","summary":"FibroGen Inc. reported total revenue from continuing operations of $1.1 million for the third quarter of 2025, up from $0.1 million in the same period of 2024. The company recorded a net loss from continuing operations of $13.1 million, or $3.25 per basic and diluted share, compared to a net loss of $48.3 million, or $12.01 per basic and diluted share, one year ago. As of September 30, 2025, FibroGen reported cash, cash equivalents, accounts receivable, and investments totaling $121.1 million, with expectations that these resources will fund operating plans into 2028. During the quarter, FibroGen completed the sale of its China operations to AstraZeneca for approximately $220 million and initiated a Phase 2 monotherapy trial of FG-3246 and its companion diagnostic FG-3180, with an interim analysis expected in the second half of 2026. The company also remains on track to submit a Phase 3 protocol for roxadustat in LR-MDS in the fourth quarter of 2025.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL1zlJMR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FGEN","BK4139","BK4505"],"gpt_icon":0},{"id":"2582385174","title":"FibroGen Inc: Q3 EPS $49.61","url":"https://stock-news.laohu8.com/highlight/detail?id=2582385174","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582385174?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:02","pubTimestamp":1762808521,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nPLX2165E6:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4505","FGEN"],"gpt_icon":0},{"id":"2581882831","title":"FibroGen Inc  expected to post a loss of $4.00 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581882831","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581882831?lang=en_us&edition=fundamental","pubTime":"2025-11-08 05:07","pubTimestamp":1762549641,"startTime":"0","endTime":"0","summary":"FibroGen Inc  expected to post a loss of $4.00 a share - Earnings Preview FibroGen Inc FGEN.OQ FGEN.O is expected to  show a fall in quarterly revenue when it reports  results on November 10 for the p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ2UU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FGEN","BK4139","BK4505"],"gpt_icon":0},{"id":"2581049031","title":"BRIEF-Fibrogen Inc - Receives $6.4 Million Payment From Astrazeneca Treasury Limited - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2581049031","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581049031?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:37","pubTimestamp":1762468659,"startTime":"0","endTime":"0","summary":"BRIEF-Fibrogen Inc - Receives $6.4 Million Payment From Astrazeneca Treasury Limited - SEC FilingNov 7  - FibroGen Inc FGEN.O:FIBROGEN INC - RECEIVES $6.4 MILLION PAYMENT FROM ASTRAZENECA TREASURY LIMITED - SEC FILINGSource text: [ID:n0001193125-25-269529]Further company coverage: FGEN.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nFWN3WI2YA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","FGEN","BK4139"],"gpt_icon":0},{"id":"2581861045","title":"FibroGen Receives $6.4 Million Payment from AstraZeneca","url":"https://stock-news.laohu8.com/highlight/detail?id=2581861045","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581861045?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:38","pubTimestamp":1762465088,"startTime":"0","endTime":"0","summary":"FibroGen ( ($FGEN) ) has provided an announcement. On November 6, 2025, FibroGen, Inc. received a $6.4 million payment from AstraZeneca, fulfilling...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fibrogen-receives-6-4-million-payment-from-astrazeneca?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fibrogen-receives-6-4-million-payment-from-astrazeneca?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FGEN","BK4139","BK4505"],"gpt_icon":0},{"id":"2581048968","title":"FibroGen Receives $6.4 Million Payment From AstraZeneca Following China Operations Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2581048968","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581048968?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:21","pubTimestamp":1762464088,"startTime":"0","endTime":"0","summary":"FibroGen, Inc. has received a $6.4 million payment from AstraZeneca Treasury Limited, completing the first holdback outlined in the share purchase agreement related to the sale of FibroGen's China operations. The agreement, initially executed on February 20, 2025, saw FibroGen sell its China business through FibroGen International  Ltd. to AstraZeneca for a total consideration of approximately $220 million. The latest payment includes $6.0 million from the initial holdback, released after final net cash adjustments, and an additional $0.4 million following these adjustments. A remaining $4.0 million holdback is set to be released, net of any indemnity claims, nine months after the closing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL129Sp6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1267930813.SGD","LU0640478417.SGD","LU0211326755.USD","LU1003076772.USD","LU1003077747.HKD","LU0211326839.USD","LU1487256676.USD","LU0158827948.USD","LU0792757196.USD","LU0964806797.USD","LU0058720904.USD","LU0708994859.HKD","SGXZ57979304.SGD","LU0553294199.USD","LU0969580561.USD","LU0997586432.USD","LU0784384876.USD","LU0211327993.USD","LU0345777147.USD","LU0784383803.USD","LU1496350502.SGD","LU1153584641.USD","IE00BKPKM643.USD","SG9999001176.SGD","LU1323610961.USD","LU1057294990.SGD","LU1989772923.USD","03165","LU2114397693.USD","LU0047473722.SGD","LU0310799852.SGD","LU0052756011.USD","LU1019632923.USD","LU2112291526.USD","LU1061106388.HKD","IE00B3T34201.USD","BK4139","AZN.UK","LU0784385840.USD","LU0972486137.USD","LU0310800965.SGD","LU0289739699.SGD","LU0203347892.USD","LU0757432116.USD","LU0266013472.USD","FGEN","LU0496365809.HKD","LU0963555726.SGD","LU1496350171.SGD","LU0545039389.USD"],"gpt_icon":0},{"id":"2570085047","title":"BUZZ-FibroGen rises after company begins mid-stage study for prostate cancer therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2570085047","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570085047?lang=en_us&edition=fundamental","pubTime":"2025-09-25 00:06","pubTimestamp":1758729976,"startTime":"0","endTime":"0","summary":"BUZZ-FibroGen rises after company begins mid-stage study for prostate cancer therapy** Shares of drug developer FibroGen FGEN.O rise 2.3% to $12.25 ** Company says it has began testing its experimental therapy, FG-3246, in patients with metastatic castration-resistant prostate cancer in a mid-stage study** The condition is an advanced stage of prostate cancer in which the cancer has spread to distant parts of the body and continues to grow and progress despite hormonal therapy aimed at lowering testosterone** The trial will also evaluate how well FG-3180 works as a diagnostic and predictive PET imaging agent, which uses the same CD46-targeted antibody as FG-3246** Company expects results from the interim analysis of a 75-patient mid-stage study in the second half of 2026** Including session's moves, stock up 7.5% YTD ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nL3N3VB150:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FGEN","BK4505","BK4139"],"gpt_icon":0},{"id":"2570085248","title":"William Blair Remains a Hold on FibroGen (FGEN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2570085248","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570085248?lang=en_us&edition=fundamental","pubTime":"2025-09-24 23:57","pubTimestamp":1758729447,"startTime":"0","endTime":"0","summary":"In a report released today, Andy Hsieh from William Blair reiterated a Hold rating on FibroGen. The company’s shares opened today at $12.23. Accord...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/william-blair-remains-a-hold-on-fibrogen-fgen-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/william-blair-remains-a-hold-on-fibrogen-fgen-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FGEN","BK4139","BK4505"],"gpt_icon":0},{"id":"2569700760","title":"FibroGen Price Target Maintained With a $43.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2569700760","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569700760?lang=en_us&edition=fundamental","pubTime":"2025-09-24 22:35","pubTimestamp":1758724500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FGEN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 24, 2025 10:35 ET (14:35 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FGEN"],"gpt_icon":0},{"id":"2569701169","title":"FibroGen’s Strategic and Financial Advancements: A Positive Outlook on FG-3246 and Roxadustat","url":"https://stock-news.laohu8.com/highlight/detail?id=2569701169","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569701169?lang=en_us&edition=fundamental","pubTime":"2025-09-24 20:35","pubTimestamp":1758717322,"startTime":"0","endTime":"0","summary":"Analyst Matthew Keller from H.C. Wainwright reiterated a Buy rating on FibroGen and keeping the price target at $43.00. Matthew Keller’s rating is ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/fibrogens-strategic-and-financial-advancements-a-positive-outlook-on-fg-3246-and-roxadustat-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/fibrogens-strategic-and-financial-advancements-a-positive-outlook-on-fg-3246-and-roxadustat-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4162","BK4505","FGEN","FG"],"gpt_icon":0},{"id":"2569703281","title":"BRIEF-FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2569703281","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569703281?lang=en_us&edition=fundamental","pubTime":"2025-09-24 19:10","pubTimestamp":1758712217,"startTime":"0","endTime":"0","summary":"BRIEF-FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate CancerSept 24 (Reuters) - FibroGen Inc FGEN.O:FIBROGEN I","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nTUABWVXRB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","FGEN","BK4139"],"gpt_icon":0},{"id":"2569703520","title":"FibroGen Launches Phase 2 Trial of FG-3246 for mCRPC, Evaluates FG-3180 as Companion PET Imaging Biomarker","url":"https://stock-news.laohu8.com/highlight/detail?id=2569703520","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569703520?lang=en_us&edition=fundamental","pubTime":"2025-09-24 19:00","pubTimestamp":1758711624,"startTime":"0","endTime":"0","summary":"FibroGen Inc. has announced the initiation of a Phase 2 monotherapy, dose-optimization trial of FG-3246, a first-in-class antibody-drug conjugate  targeting CD46-expressing cancer lesions in patients with metastatic castration-resistant prostate cancer . The trial, which will enroll 75 patients in the post-androgen receptor signaling inhibitor and pre-chemotherapy setting, will also evaluate FG-3180 as a companion PET imaging agent and potential predictive biomarker for patient selection. An interim analysis of the Phase 2 study is expected in the second half of 2026. Additionally, topline results from an ongoing investigator-sponsored study of FG-3246 in combination with enzalutamide in mCRPC patients are anticipated in the fourth quarter of 2025. No results have been presented at this time.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nNDL5gs5jX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B64PRP62.GBP","NDAQ","LU2210150020.SGD","LU2210149790.SGD","BK4588","FGEN","LU2095319765.USD","BK4585","IE00B3QW5Z07.USD","BK4139","BK4505","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2569703961","title":"FibroGen Inc - Interim Analysis of Trial Expected in 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2569703961","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569703961?lang=en_us&edition=fundamental","pubTime":"2025-09-24 19:00","pubTimestamp":1758711600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nTUABWVXRB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4505","FGEN"],"gpt_icon":0},{"id":"2569031957","title":"FibroGen Inc - Topline Results of FG-3246 in Combination With Enzalutamide in Patients With Mcrpc Enzalutamide Expected Q4 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2569031957","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569031957?lang=en_us&edition=fundamental","pubTime":"2025-09-24 19:00","pubTimestamp":1758711600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nTUABWVXRB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FGEN","BK4505"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fibrogen.com","stockEarnings":[{"period":"1week","weight":0.0526},{"period":"1month","weight":-0.2289},{"period":"3month","weight":-0.2611},{"period":"6month","weight":0.1028},{"period":"1year","weight":-0.0628},{"period":"ytd","weight":-0.3575}],"compareEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0.018},{"period":"3month","weight":0.0473},{"period":"6month","weight":0.1313},{"period":"1year","weight":0.1296},{"period":"ytd","weight":0.1654}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.727273,"avgChangeRate":0.196681},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.032668},{"month":3,"riseRate":0.181818,"avgChangeRate":-0.060681},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.133734},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.039352},{"month":6,"riseRate":0.636364,"avgChangeRate":-0.001658},{"month":7,"riseRate":0.545455,"avgChangeRate":-0.034699},{"month":8,"riseRate":0.363636,"avgChangeRate":0.01162},{"month":9,"riseRate":0.454545,"avgChangeRate":-0.009378},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.070226},{"month":11,"riseRate":0.727273,"avgChangeRate":0.07854},{"month":12,"riseRate":0.636364,"avgChangeRate":0.093241}],"exchange":"NASDAQ","name":"FibroGen","nameEN":"FibroGen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"FibroGen(FGEN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest FibroGen(FGEN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"FibroGen,FGEN,FibroGen股票,FibroGen股票老虎,FibroGen股票老虎国际,FibroGen行情,FibroGen股票行情,FibroGen股价,FibroGen股市,FibroGen股票价格,FibroGen股票交易,FibroGen股票购买,FibroGen股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"FibroGen(FGEN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest FibroGen(FGEN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction